U.S. health regulators on Wednesday said Abbott Laboratories' cholesterol drug Trilipix may not lower the risk of a heart attack or stroke. The U.S. Food and Drug Administration reviewed data from a study, known as Accord-Lipid, that tested the efficacy and safety of a combination of fenofibrate and a cholesterol-lowering statin against the statin alone, in patients with type 2 diabetes. Fenofibrate is similar to the active ingredient in Abbott's Trilipix. There was no significant difference in the risk of experiencing a major adverse cardiac event between the two groups, FDA said on its website.
